SECAUCUS, N.J., Nov. 3, 2020 /PRNewswire/ -- Quest Diagnostics
Incorporated (NYSE: DGX), the world's leading provider of
diagnostic information services, announced that it is scheduled to
speak at the Credit Suisse 29th Annual Virtual
Healthcare Conference. Steve Rusckowski, Chairman, President
& CEO will discuss the company's vision, goals and two-point
strategy to accelerate growth and drive operational excellence, and
the company's current perspective on the impact of the COVID-19
pandemic. The presentation is scheduled for Tuesday, November 10, 2020 at 11:45 a.m. Eastern Time.
The presentation will be webcast live during the conference and
will be available on the company's investor relations page which
can be accessed at ir.QuestDiagnostics.com. In addition, the
archived webcast will be available within 48 hours after the
conclusion of the live event and will remain available until
December 10, 2020.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health
outcomes. Derived from the world's largest database of clinical lab
results, our diagnostic insights reveal new avenues to identify and
treat disease, inspire healthy behaviors and improve health care
management. Quest Diagnostics annually serves one in three adult
Americans and half the physicians and hospitals in the United States, and our 47,000 employees
understand that, in the right hands and with the right context, our
diagnostic insights can inspire actions that transform lives.
www.QuestDiagnostics.com.
About COVID-19 testing at Quest Diagnostics
Quest Diagnostics is at the forefront of the response to the
COVID-19 pandemic, working to broaden access to laboratory insights
to help us all lead healthier lives. We provide both
molecular diagnostic and antibody serology tests to aid in the
diagnosis of COVID-19 and immune response. Our COVID-19 test
services are based on tests that have received FDA emergency use
authorization and which also meet our high standards for
quality. We are providing these test services under the Public
Readiness and Emergency Preparedness Act. We provide data
on COVID-19 testing to various federal and state public health
authorities, including the Centers for Disease Control and
Prevention, and participate in studies with government and private
institutions, aiding COVID-19 public health response and research.
Through our team of dedicated phlebotomists, air fleet team,
couriers and laboratory professionals, Quest Diagnostics works hard
every day to help patients and communities across the United
States access quality COVID-19 testing.
The antibody tests and the molecular tests (together "All
tests") have not been FDA cleared or approved; All tests have been
authorized by FDA under EUAs for use by authorized laboratories;
The antibody tests have been authorized only for the detection of
IgG antibodies against SARS-CoV-2, not for any other viruses or
pathogens; The molecular tests have been authorized only for the
detection of nucleic acid from SARSCoV-2, not for any other viruses
or pathogens; and, All tests are only authorized for the duration
of the declaration that circumstances exist justifying the
authorization of emergency use of in vitro diagnostics for
detection and/or diagnosis of COVID-19 under Section 564(b)(1) of
the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is
terminated or revoked sooner.
For more information about the latest developments with our
COVID-19 testing, visit:
newsroom.questdiagnostics.com/COVIDTestingUpdates
View original content to download
multimedia:http://www.prnewswire.com/news-releases/quest-diagnostics-to-speak-at-the-credit-suisse-29th-annual-virtual-healthcare-conference-301165935.html
SOURCE Quest Diagnostics